QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
Log in
NASDAQ:STSA

Satsuma Pharmaceuticals News Headlines

$4.50
-0.18 (-3.85 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.37
Now: $4.50
$4.65
50-Day Range
$3.56
MA: $4.04
$4.54
52-Week Range
$3.50
Now: $4.50
$36.10
Volume402,613 shs
Average Volume736,098 shs
Market Capitalization$78.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Satsuma Pharmaceuticals (NASDAQ STSA) News Headlines Today

Source:
SourceHeadline
HC Wainwright Trims Satsuma Pharmaceuticals (NASDAQ:STSA) Target Price to $7.00HC Wainwright Trims Satsuma Pharmaceuticals (NASDAQ:STSA) Target Price to $7.00
marketbeat.com - September 21 at 7:42 AM
Satsuma Pharmaceuticals (NASDAQ:STSA) Price Target Raised to $33.00Satsuma Pharmaceuticals (NASDAQ:STSA) Price Target Raised to $33.00
marketbeat.com - August 14 at 11:53 AM
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Receives Average Recommendation of "Buy" from AnalystsSatsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Receives Average Recommendation of "Buy" from Analysts
americanbankingnews.com - November 29 at 3:41 AM
Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx ConferenceSatsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
finance.yahoo.com - November 24 at 7:21 PM
Satsuma Pharmaceuticals (NASDAQ:STSA) Shares Up 5.6%Satsuma Pharmaceuticals (NASDAQ:STSA) Shares Up 5.6%
americanbankingnews.com - November 20 at 7:15 PM
Satsuma Pharmaceuticals (NASDAQ:STSA) Issues  Earnings ResultsSatsuma Pharmaceuticals (NASDAQ:STSA) Issues Earnings Results
americanbankingnews.com - November 11 at 2:56 PM
Mizuho Lowers Satsuma Pharmaceuticals (NASDAQ:STSA) Price Target to $3.50Mizuho Lowers Satsuma Pharmaceuticals (NASDAQ:STSA) Price Target to $3.50
americanbankingnews.com - November 11 at 10:51 AM
Satsuma Pharmaceuticals (NASDAQ:STSA) Trading Up 5.2%Satsuma Pharmaceuticals (NASDAQ:STSA) Trading Up 5.2%
americanbankingnews.com - November 5 at 9:54 PM
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Sees Significant Growth in Short InterestSatsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Sees Significant Growth in Short Interest
americanbankingnews.com - November 5 at 3:01 AM
Satsuma Pharmaceuticals to to participate in the following November Virtual Investor ConferencesSatsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences
finance.yahoo.com - November 2 at 5:19 PM
Satsuma Pharmaceuticals Enters Oversold TerritorySatsuma Pharmaceuticals Enters Oversold Territory
nasdaq.com - October 6 at 7:31 AM
Satsuma: Not All Over For Migraine Treatment Despite Trial FailureSatsuma: Not All Over For Migraine Treatment Despite Trial Failure
seekingalpha.com - September 25 at 7:19 PM
NetworkNewsBreaks - Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research ReportNetworkNewsBreaks - Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research Report
marketwatch.com - September 12 at 7:38 PM
Satsuma Plunges on Disappointing Data on Migraine TreatmentSatsuma Plunges on Disappointing Data on Migraine Treatment
finance.yahoo.com - September 11 at 3:01 PM
Analysts bails on Satsuma Pharma after underwhelming STS101 data in migraneAnalysts bails on Satsuma Pharma after underwhelming STS101 data in migrane
seekingalpha.com - September 11 at 10:00 AM
Analysts bail on Satsuma Pharma after STS101 flopAnalysts bail on Satsuma Pharma after STS101 flop
seekingalpha.com - September 11 at 10:00 AM
Mid-Afternoon Market Update: Nasdaq Tumbles 200 Points; Satsuma Pharmaceuticals Shares PlungeMid-Afternoon Market Update: Nasdaq Tumbles 200 Points; Satsuma Pharmaceuticals Shares Plunge
benzinga.com - September 10 at 2:47 PM
This Late-Stage Study Is Giving Satsuma Pharma Stock MigrainesThis Late-Stage Study Is Giving Satsuma Pharma Stock Migraines
msn.com - September 10 at 1:56 PM
Satsuma Pharmas STS101 flunks late-stage migraine study, shares down 84%Satsuma Pharma's STS101 flunks late-stage migraine study, shares down 84%
seekingalpha.com - September 10 at 1:56 PM
Stock Alert: Satsuma Pharmaceuticals Plunges 73% As Late Stage Trial Of Migraine Treatment FailsStock Alert: Satsuma Pharmaceuticals Plunges 73% As Late Stage Trial Of Migraine Treatment Fails
nasdaq.com - September 10 at 1:56 PM
Why Satsuma Pharmaceuticals Stock Is Plummeting TodayWhy Satsuma Pharmaceuticals Stock Is Plummeting Today
fool.com - September 10 at 12:32 PM
Satsumas Migraine Drug Flunks Late-Stage Study, Stock Sinks To Record LowSatsuma's Migraine Drug Flunks Late-Stage Study, Stock Sinks To Record Low
feeds.benzinga.com - September 10 at 10:59 AM
Satsuma Pharma: STS101 Fails To Meet Statistical Significance On Co-primary EndpointsSatsuma Pharma: STS101 Fails To Meet Statistical Significance On Co-primary Endpoints
nasdaq.com - September 10 at 8:55 AM
Satsuma Pharmaceuticals Announces Topline Results from EMERGE Phase 3 Trial of STS101 for the Acute Treatment of MigraineSatsuma Pharmaceuticals Announces Topline Results from EMERGE Phase 3 Trial of STS101 for the Acute Treatment of Migraine
finance.yahoo.com - September 10 at 8:55 AM
Satsuma Pharmaceuticals to Participate in September Virtual Investor ConferencesSatsuma Pharmaceuticals to Participate in September Virtual Investor Conferences
feeds.benzinga.com - September 3 at 7:54 PM
Satsuma Pharmaceuticals Provides Business Update and Reports  Second Quarter 2020 Financial ResultsSatsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
finance.yahoo.com - August 12 at 9:23 AM
Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101
finance.yahoo.com - August 6 at 5:12 PM
Benzinga's Top Upgrades, Downgrades For July 27, 2020Benzinga's Top Upgrades, Downgrades For July 27, 2020
finance.yahoo.com - July 27 at 1:20 PM
Thomas M. Soloway on Satsuma Pharmas boardThomas M. Soloway on Satsuma Pharma's board
seekingalpha.com - July 7 at 4:49 PM
Satsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of DirectorsSatsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of Directors
finance.yahoo.com - July 7 at 4:49 PM
Satsuma Pharmaceuticals to Present Two Posters at the American Headache Society’s Annual Scientific Meeting Hosted via a Virtual Meeting PlatformSatsuma Pharmaceuticals to Present Two Posters at the American Headache Society’s Annual Scientific Meeting Hosted via a Virtual Meeting Platform
finance.yahoo.com - June 11 at 8:13 PM
Satsuma Pharmaceuticals, Inc. (STSA): Hedge Funds In Wait-and-See ModeSatsuma Pharmaceuticals, Inc. (STSA): Hedge Funds In Wait-and-See Mode
finance.yahoo.com - June 10 at 6:00 PM
Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of MigraineSatsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine
finance.yahoo.com - June 1 at 7:56 PM
Satsuma Pharmaceuticals to To Present at the Jefferies Virtual Healthcare ConferenceSatsuma Pharmaceuticals to To Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 27 at 1:30 PM
Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual PlatformSatsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform
finance.yahoo.com - May 18 at 7:02 PM
Satsuma Pharmaceuticals EPS misses by $0.01Satsuma Pharmaceuticals EPS misses by $0.01
seekingalpha.com - May 12 at 6:21 PM
Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business ResultsSatsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results
finance.yahoo.com - May 12 at 6:21 PM
Satsuma Pharmaceuticals to Host Key Opinion Leader Event: STS101 and the Acute Treatment of MigraineSatsuma Pharmaceuticals to Host Key Opinion Leader Event: STS101 and the Acute Treatment of Migraine
finance.yahoo.com - April 28 at 5:42 PM
Satsuma Pharmaceuticals EPS beats by $0.20Satsuma Pharmaceuticals EPS beats by $0.20
seekingalpha.com - March 10 at 4:21 PM
Satsuma Pharmaceuticals Appoints Rob Janosky as Chief Commercial OfficerSatsuma Pharmaceuticals Appoints Rob Janosky as Chief Commercial Officer
finance.yahoo.com - March 5 at 8:53 PM
Satsuma Pharmaceuticals Inc.Satsuma Pharmaceuticals Inc.
www.barrons.com - March 4 at 6:33 PM
Satsuma Pharmaceuticals IncSatsuma Pharmaceuticals Inc
www.bloomberg.com - March 1 at 10:26 PM
Satsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare ConferenceSatsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 18 at 8:15 AM
Mizuho likes AbbVie in premarket analyst actionMizuho likes AbbVie in premarket analyst action
seekingalpha.com - February 6 at 7:23 AM
Satsuma Pharma rallies on encouraging data on lead candidate, up 11%Satsuma Pharma rallies on encouraging data on lead candidate, up 11%
seekingalpha.com - January 29 at 1:18 PM
Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face PainSatsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain
finance.yahoo.com - January 28 at 7:46 PM
Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business ResultsSatsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results
finance.yahoo.com - January 12 at 4:51 PM
Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx ConferenceSatsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
finance.yahoo.com - January 12 at 4:51 PM
Hedge Funds Have Never Been This Bullish On Satsuma Pharmaceuticals, Inc. (STSA)Hedge Funds Have Never Been This Bullish On Satsuma Pharmaceuticals, Inc. (STSA)
finance.yahoo.com - January 12 at 4:51 PM
This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.